NBW Capital LLC Has $250,000 Holdings in Johnson & Johnson (NYSE:JNJ)

NBW Capital LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 22.3% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,580 shares of the company’s stock after acquiring an additional 288 shares during the period. NBW Capital LLC’s holdings in Johnson & Johnson were worth $250,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Christopher J. Hasenberg Inc acquired a new stake in Johnson & Johnson during the first quarter worth about $31,000. Keener Financial Planning LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $40,000. WFA Asset Management Corp grew its stake in shares of Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after purchasing an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Johnson & Johnson in the 4th quarter worth approximately $44,000. Finally, Disciplined Equity Management Inc. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $45,000. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Trading Up 2.1 %

Shares of JNJ stock traded up $3.38 during trading hours on Friday, reaching $164.14. The company had a trading volume of 11,280,357 shares, compared to its average volume of 7,234,699. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.07 and a quick ratio of 0.85. The firm has a market cap of $395.12 billion, a price-to-earnings ratio of 10.23, a P/E/G ratio of 2.63 and a beta of 0.52. The company has a 50 day moving average of $149.73 and a 200 day moving average of $153.14.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, beating analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. Johnson & Johnson’s revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analyst Ratings Changes

Several research firms have issued reports on JNJ. TD Cowen dropped their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research note on Thursday, July 18th. Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Daiwa America cut shares of Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Sunday, June 30th. Finally, Sanford C. Bernstein increased their price target on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Eight research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $173.00.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.